A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

Recruiting

Phase 1

PD-32766D & PD-32766TA Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

Sponsor:

PeptiDream Inc.

Code:

NCT07688187

Conditions

Clear Cell Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PD-32766D (a Copper-64 [64Cu] labeled peptide)

PD-32766T (an Actinium-225 [225Ac] labeled peptide)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-12. This information was provided to ClinicalTrials.gov by PeptiDream Inc. on 2026-07-07.